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Triamcinolone with Vitamin D Synergistic Efficacy in Psoriasis 
Steven J. Repas, Jeffrey B. Travers, M.D., Ph.D. 
Department of Pharmacology & Toxicology, Department of Dermatology 
Background: 
• Psoriasis is one of the most 
common skin conditions in the
United States affecting more
than 8 million people.
• High amounts of vitamin D has
been shown to be effective in
treatment of psoriasis. It also
has a well-documented safety
profile at the doses and
duration that will be used 
during this study.
• Triamcinolone and other topical
corticosteroids are considered
a first line treatment for mild to
moderate psoriasis with a well-
documented safety profile. 
• Individually both of these 
medications have shown 
effectiveness in the 
management and treatment of
mild to moderate psoriasis. 
• This study is designed to test 
whether a combination therapy
of topical 0.1% triamcinolone
with 40,000 IU vitamin D3 daily
is effective in treating mild to
moderate psoriasis. 
Methods: 
• To test this, we planned to 
enroll up to 24 subjects whom 
are age 18 and older with mild 
to moderate psoriasis (2%+ 
PASI). 
• Currently, we have 7 subjects
enrolled These subjects will be
treated with topical 0.1%
triamcinolone and oral 40,000
IU vitamin D3. 
• The patients were monitored
monthly until completion of 
trial at 6 months.
• During the 6-month period, 
patients had monthly blood 
draws (CBC, CMP, iPTH, 25-
hydroxyvitamin D, 1,25 
dihydroxyvitamin D), PASI 
scores (self-calculated), sPGA 
(self-calculated), Quality of 
Life assessment (DLQI), PHQ-
9, vital signs, height and 
weight 
Results: 
• Preliminary analysis of 5 subjects showed a 
consistent decrease of PASI score from initial 
screening appointment (average score of 
6.42) to final appointment on week 24 
(average score of 4.72). 
• There was a modest decrease in sPGA for all 
subjects with an average starting sPGA of 2.6
and an average final sPGA of 2 
• There was a modest improvement in PHQ9
for all patients with a starting average score 
of 6 and a final average score of 3. Further,
there was a mild improvement in DLQI score 
with a starting average score of 3 and a final
average score of 2.25. 
• From a lab value perspective, there were no
patients with recorded hypercalcemia or
other recorded electrolyte or metabolic
derangements throughout the duration of the
study. (average Calcium: 9.5). 
• There was a moderate average increase in 25-
hydroxyvitamin D levels (starting average 
value: 24, final average value: 68). Finally, 
there was a modest decrease in average iPTH 
with an average starting value of 50.6 and an 









1 12.8 5.8 3 3 
2 4 1.6 2 1 
3 7.5 4.6 3 2 
4 3.6 4.4 3 2 
5 4.2 7.2 2 2 
Average 6.42 4.72 2.6 2 
Conclusions: 
• Vitamin D combined with 
triamcinolone showed a
decrease in PASI and SGA in 
several patients with
psoriasis. 
• While preliminary results are
encouraging, more subjects
are needed to make 
definitive conclusions on the
efficaciousness of vitamin D
combined with triamcinolone
in patients with mild to
moderate psoriasis. 
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